Ampiroxicam

Catalog No.S4011 Batch:S401101

Print

Technical Data

Formula

C20H21N3O7S
Molecular Weight 447.46 CAS No. 99464-64-9
Solubility (25°C)* In vitro DMSO 90 mg/mL (201.13 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 4.5mg/ml (10.06mM) Taking the 1 mL working solution as an example, add 50 μL of 90 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 0.64mg/ml (1.43mM) Taking the 1 mL working solution as an example, add 50 μL of 12.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ampiroxicam (CP 65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.
Targets
COX [1]
In vitro Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells. [1] This compound (50 μM) results in decreased expression of Sp1, Sp3, Sp4, and VEGFR1 proteins in Panc-1 cells and L3.6pl cells as determined by Western blot analysis. It (50 μM) results in increased phosphorylation of MAPK1/2 in Panc-1 cells and L3.6pl cells. [2]
In vivo Ampiroxicam inhibits the stretching response in mice induced by phenylbenzoquinone (PBQ) with maximum protective effect (MPE) of 2 mg/kg. This compound inhibits swelling in a dose-responsive manner in the rat foot edema (RFE) assay with ED50 of 28 mg/kg at single oral dose and 7.8 mg/kg at 5 daily oral dose. It blocks primary and secondary lesion development in rat adjuvant arthritis with ED50 of 2.2 mg/kg and 0.5 mg/kg, respectively. This chemical (3.2 mg/kg) leads to a plasma concentration of 12 μg/mL at a Tmax of 2 hours for piroxicam derived from ampiroxicam in rats. [3] Ultraviolet-A (UVA)-irradiated 1% this compound sensitized in guinea pigs shows positive reaction in the patch testing to UVA-irradiated 1% this chemical and 1% thiosalicylate (TOS). Concentration of this compound is easily reduced by the increase in UVA irradiation doses, as compared with that of piroxicam. [4]
Features Ampiroxicam is a non-acidic ether carbonate prodrug of piroxicam.

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    Panc-1 cells

  • Concentrations

    150 μM

  • Incubation Time

    48 hours

  • Method

    Panc-1 cells are plated in DME/F12 medium with 5% fetal bovine serum and treated on the next day with vehicle (0.1% DMSO) or various concentrations of Ampiroxicam. Cells are counted at the indicated times with a Coulter Z1 cell counter. Each experiment is done in triplicate, and results are expressed as means, with error bars representing 95% confidence intervals (CIs).
Animal Study:[3]
  • Animal Models

    Rats with adjuvant arthritis

  • Dosages

    3.2 mg/kg

  • Administration

    Orally

References

  • https://pubmed.ncbi.nlm.nih.gov/16788159/
  • https://pubmed.ncbi.nlm.nih.gov/17409437/
  • https://pubmed.ncbi.nlm.nih.gov/8304243/
  • https://pubmed.ncbi.nlm.nih.gov/10527378/

Selleck's Ampiroxicam Has Been Cited by 1 Publication

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805] PubMed: 39581704

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.